Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models

被引:98
作者
Sonnen, Joshua A. [2 ,3 ,4 ]
Breitner, John C. [2 ,3 ,4 ]
Lovell, Mark A. [2 ,3 ,4 ]
Markesbery, William R. [2 ,3 ,4 ]
Quinn, Joseph F. [2 ,3 ,4 ]
Montine, Thomas J. [1 ,2 ,3 ,4 ]
机构
[1] Univ Washington, Dept Pathol, Harborview Med Ctr, Seattle, WA 98104 USA
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA
[3] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA
[4] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA
关键词
Alzheimer's disease; mild cognitive impairement; oxidative damage; anti-oxidants;
D O I
10.1016/j.freeradbiomed.2008.04.022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Advances in our understanding of the etiologies and pathogenesis of Alzheimer's disease (AD) highlight a role for free radical-mediated injury to brain regions from early stages of this illness. Here we will review the evidence from transgenic mouse models of AD, autopsy samples, and human biofluids obtained during life paying particular attention to the stage of disease. In addition, we Will review the epidemiologic literature that addresses the potential of anti-oxidants to prevent incident dementia from AD, and the clinical trial literature that addresses anti-oxidant preventative or therapeutic strategies for different stage of AD. Future efforts in preclinical models and ultimately clinical trials are needed to define optimally effective agents and combinations, doses, and timing to suppress safely this facet of AD. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:219 / 230
页数:12
相关论文
共 180 条
[1]   APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer's disease [J].
Abdul, HM ;
Wenk, GL ;
Gramling, M ;
Hauss-Wegrzyniak, B ;
Butterfield, DA .
NEUROSCIENCE LETTERS, 2004, 368 (02) :148-150
[2]   Controlled trial of N-acetyleysteine for patients with probable Alzheimer's disease [J].
Adair, JC ;
Knoefel, JE ;
Morgan, N .
NEUROLOGY, 2001, 57 (08) :1515-1517
[3]   Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment [J].
Andreasen, N ;
Minthon, L ;
Vanmechelen, E ;
Vanderstichele, H ;
Davidsson, P ;
Winblad, B ;
Blennow, K .
NEUROSCIENCE LETTERS, 1999, 273 (01) :5-8
[4]   Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment [J].
Andreasen, N ;
Vanmechelen, E ;
Vanderstichele, H ;
Davidsson, P ;
Blennow, K .
ACTA NEUROLOGICA SCANDINAVICA, 2003, 107 :47-51
[5]   Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology [J].
Apelt, J ;
Bigl, M ;
Wunderlich, P ;
Schliebs, R .
INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 2004, 22 (07) :475-484
[6]   CSF phosphorylated tau protein and mild cognitive impairment: a prospective study [J].
Arai, H ;
Ishiguro, K ;
Ohno, H ;
Moriyama, M ;
Itoh, N ;
Okamura, N ;
Matsui, T ;
Morikawa, Y ;
Horikawa, E ;
Kohno, H ;
Sasaki, H ;
Imahori, K .
EXPERIMENTAL NEUROLOGY, 2000, 166 (01) :201-203
[7]   DISTRIBUTION OF ALZHEIMER-TYPE PATHOLOGICAL-CHANGES IN NONDEMENTED ELDERLY INDIVIDUALS MATCHES THE PATTERN IN ALZHEIMERS-DISEASE [J].
ARRIAGADA, PV ;
MARZLOFF, K ;
HYMAN, BT .
NEUROLOGY, 1992, 42 (09) :1681-1688
[8]   NEUROPATHOLOGICAL INDEXES OF ALZHEIMERS-DISEASE IN DEMENTED AND NONDEMENTED PERSONS AGED 80 YEARS AND OLDER [J].
BERG, L ;
MCKEEL, DW ;
MILLER, JP ;
BATY, J ;
MORRIS, JC .
ARCHIVES OF NEUROLOGY, 1993, 50 (04) :349-358
[9]   Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry [J].
Bohnstedt, KC ;
Karlberg, B ;
Wahlund, LO ;
Jönhagen, ME ;
Basun, H ;
Schmidt, S .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 796 (01) :11-19
[10]   NSAIDs and Alzheimer's disease: how far to generalise from trials? [J].
Breitner, JCS .
LANCET NEUROLOGY, 2003, 2 (09) :527-527